Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 02, 2024

BUY
$0.75 - $1.26 $57 - $95
76 Added 0.03%
291,245 $218,000
Q3 2023

Oct 27, 2023

SELL
$1.5 - $2.33 $483,238 - $750,630
-322,159 Reduced 52.53%
291,169 $436,000
Q2 2023

Aug 07, 2023

BUY
$0.68 - $1.59 $417,063 - $975,191
613,328 New
613,328 $975,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Acuitas Investments, LLC Portfolio

Follow Acuitas Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuitas Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuitas Investments, LLC with notifications on news.